The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies

• Published in: Regenerative medicine Vol. 7; no. 3; pp. 429 - 438
• Main Authors: Rose, James B, Williams, David J
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.05.2012
• Subjects: adoption; Biomedical Technology - economics; Biomedical Technology - legislation & jurisprudence; Canada; Clinical Trials as Topic - economics; Clinical Trials as Topic - legislation & jurisprudence; Economic aspects; Government Regulation; Health care industry; Health Care Sector - economics; Health Care Sector - legislation & jurisprudence; healthcare; Humans; Laws, regulations and rules; market; NHS; Regenerative medicine; Regenerative Medicine - economics; Regenerative Medicine - legislation & jurisprudence; Regenerative Medicine - methods; reimbursement; Reimbursement Mechanisms - economics; Single-Payer System - economics; Single-Payer System - legislation & jurisprudence; UK; United Kingdom; United Kingdom
• ISSN: 1746-0751; 1746-076X; 1746-076X
• DOI: 10.2217/rme.11.125

The UK has for many years been considered by businesses, including those based in the UK, as at best a second market for the launch of innovative medical technology products. Historically, this has been attributed to the slow pace of adoption in its National Health Service (NHS). The NHS is perceived to be subject to cost containment, high levels of fragmentation and a lack of strategic incentives to resolve its key failings as a market. Canada and Sweden offer examples of different operating models of healthcare delivery in a single payer-dominated market, and as a consequence, have evolved with different market characteristics. Together, these economies represent an important subsection of healthcare markets that are predominantly publically funded. This report examines the barriers to market entry for regenerative medicine products in these economies and attempts to evaluate the upcoming UK healthcare reforms in terms of impact on the regenerative medicine industry sector.